Safety and efficacy of Pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma

Research output: Contribution to journalReview ArticleResearchpeer-review

5 Citations (Scopus)

Abstract

Peripheral T-cell lymphoma (PTCL) represents a relatively rare group of heterogeneous non-Hodgkin lymphomas, with generally poor prognosis. Historically, there has been a lack of consensus regarding appropriate therapeutic measures for the disease, with conventional frontline chemotherapies being utilized in most cases. Following promising results obtained in 2009, the methotrexate analogue, pralatrexate, became the first drug to gain US FDA approval for the treatment of refractory PTCL. This antimetabolite was designed to have a higher affinity for reduced folate carrier (RFC) and folylpolyglutamate synthetase (FPGS). RFC is the principal transporter for cell entrance of folates and antifolates. Once inside the cell, pralatrexate is efficiently polyglutamated by FPGS. Pralatrexate has demonstrated varying degrees of efficacy in peripheral T-cell lymphoma, with response rates differing between the multiple subtypes of the disease. While phase III studies are still to be completed, early clinical trials indicate that pralatrexate is promising new therapeutic for PTCL.

Original languageEnglish
Pages (from-to)305-314
Number of pages10
JournalClinical Medicine Insights: Oncology
Volume6
DOIs
Publication statusPublished - 2012
Externally publishedYes

Keywords

  • Antifolate therapy
  • Folate metabolism
  • Methotrexate
  • Peripheral T-cell lymphoma
  • Pralatrexate

Cite this

@article{8f4284cfa31f4aa08cc50a7f2add8742,
title = "Safety and efficacy of Pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma",
abstract = "Peripheral T-cell lymphoma (PTCL) represents a relatively rare group of heterogeneous non-Hodgkin lymphomas, with generally poor prognosis. Historically, there has been a lack of consensus regarding appropriate therapeutic measures for the disease, with conventional frontline chemotherapies being utilized in most cases. Following promising results obtained in 2009, the methotrexate analogue, pralatrexate, became the first drug to gain US FDA approval for the treatment of refractory PTCL. This antimetabolite was designed to have a higher affinity for reduced folate carrier (RFC) and folylpolyglutamate synthetase (FPGS). RFC is the principal transporter for cell entrance of folates and antifolates. Once inside the cell, pralatrexate is efficiently polyglutamated by FPGS. Pralatrexate has demonstrated varying degrees of efficacy in peripheral T-cell lymphoma, with response rates differing between the multiple subtypes of the disease. While phase III studies are still to be completed, early clinical trials indicate that pralatrexate is promising new therapeutic for PTCL.",
keywords = "Antifolate therapy, Folate metabolism, Methotrexate, Peripheral T-cell lymphoma, Pralatrexate",
author = "Rodd, {Annabelle L.} and Katherine Ververis and Karagiannis, {Tom C.}",
year = "2012",
doi = "10.4137/CMO.S8536",
language = "English",
volume = "6",
pages = "305--314",
journal = "Clinical Medicine Insights: Oncology",
issn = "1179-5549",
publisher = "Libertas Academica",

}

Safety and efficacy of Pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma. / Rodd, Annabelle L.; Ververis, Katherine; Karagiannis, Tom C.

In: Clinical Medicine Insights: Oncology, Vol. 6, 2012, p. 305-314.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Safety and efficacy of Pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma

AU - Rodd, Annabelle L.

AU - Ververis, Katherine

AU - Karagiannis, Tom C.

PY - 2012

Y1 - 2012

N2 - Peripheral T-cell lymphoma (PTCL) represents a relatively rare group of heterogeneous non-Hodgkin lymphomas, with generally poor prognosis. Historically, there has been a lack of consensus regarding appropriate therapeutic measures for the disease, with conventional frontline chemotherapies being utilized in most cases. Following promising results obtained in 2009, the methotrexate analogue, pralatrexate, became the first drug to gain US FDA approval for the treatment of refractory PTCL. This antimetabolite was designed to have a higher affinity for reduced folate carrier (RFC) and folylpolyglutamate synthetase (FPGS). RFC is the principal transporter for cell entrance of folates and antifolates. Once inside the cell, pralatrexate is efficiently polyglutamated by FPGS. Pralatrexate has demonstrated varying degrees of efficacy in peripheral T-cell lymphoma, with response rates differing between the multiple subtypes of the disease. While phase III studies are still to be completed, early clinical trials indicate that pralatrexate is promising new therapeutic for PTCL.

AB - Peripheral T-cell lymphoma (PTCL) represents a relatively rare group of heterogeneous non-Hodgkin lymphomas, with generally poor prognosis. Historically, there has been a lack of consensus regarding appropriate therapeutic measures for the disease, with conventional frontline chemotherapies being utilized in most cases. Following promising results obtained in 2009, the methotrexate analogue, pralatrexate, became the first drug to gain US FDA approval for the treatment of refractory PTCL. This antimetabolite was designed to have a higher affinity for reduced folate carrier (RFC) and folylpolyglutamate synthetase (FPGS). RFC is the principal transporter for cell entrance of folates and antifolates. Once inside the cell, pralatrexate is efficiently polyglutamated by FPGS. Pralatrexate has demonstrated varying degrees of efficacy in peripheral T-cell lymphoma, with response rates differing between the multiple subtypes of the disease. While phase III studies are still to be completed, early clinical trials indicate that pralatrexate is promising new therapeutic for PTCL.

KW - Antifolate therapy

KW - Folate metabolism

KW - Methotrexate

KW - Peripheral T-cell lymphoma

KW - Pralatrexate

UR - http://www.scopus.com/inward/record.url?scp=84866060618&partnerID=8YFLogxK

U2 - 10.4137/CMO.S8536

DO - 10.4137/CMO.S8536

M3 - Review Article

VL - 6

SP - 305

EP - 314

JO - Clinical Medicine Insights: Oncology

JF - Clinical Medicine Insights: Oncology

SN - 1179-5549

ER -